View Clinical Trial (Medical Research Study)

Pilot Study of Fosamax in Spinal Cord Injury - NCT01131884-14642(Clinical Trial 651527)



ClinicalConnection.com has recently undergone an update and this page may no longer be up-to-date. Please Search For Clinical Trials to view the most current clinical trials listings.


Signup
City:  Rochester
State:  
NY
Zip Code: 14642
Conditions: Spinal Cord Injury - Osteoporosis
Purpose: Study is designed to evaluate the efficacy of oral fosamax in prevention on osteoporosis in acute spinal cord injury. Efficacy will be measured by a duel energy X-Ray absorptiometry (DEXA) scan every 6 months. Patients will complete 3 visits, screening, 6 months, 12 months and be required to take oral fosamax versus placebo weekly.
Study summary:
Criteria: Inclusion Criteria: - American Spinal Cord Injury Association (ASIA) A or American Spinal Cord Injury Association (ASIA) B Spinal Cord Injury Exclusion Criteria: - History of hypersensitivity to alendronate or other bisphosphonates - esophageal abnormality - inability to sit/stand upright for 30 minutes - creatinine clearance less than 35 milliliters/minute - hypothyroidism - malignancy - pregnancy - prolonged steroid use
Study is available at: University of Rochester
Rochester, NY 14642
United States

Primary Contact:
Mathew J Abraham, MD
Email: mathew_abraham@urmc.rochester.edu
Phone: 585-275-3274

Secondary Contact:
Kanakadurga R Poduri, MD
Email: KR_Poduri@urmc.rochester.edu
Phone: (585) 275-3274
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
Trials Alerts: If you would like to be notified of new clinical trials as they become available please register for a free account.
Data Source: ClinicalTrials.gov
Date Processed: March 23, 2011
Modifications to
this listing:		 Only selected fields are shown, please use the link above to view all information about this clinical trial.